Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (28520)	3/13/1999 8:48:00 AM
From: aknahow	Read Replies (1) \| Respond to of 32384

Thanks, I agree with that and just found a link to a current article which supports your post. But my question is really have you heard of a trial where a total number of deaths, the sum of both the treatment arm and the placebo arm, was pre established as a condition to conclusion of the trial. I am not speaking of proving the drug in question worked or not, but rather just a condition required to terminate the trial to determine if the data could be analyzed. I mentioned the probable intent to permit having a small trial accrual just to keep some from thinking setting a target for mortality was somehow evil.

To: Henry Niman who wrote (28520)	3/13/1999 6:10:00 PM
From: Spekulatius	Read Replies (5) \| Respond to of 32384

Due to the recent price drop LGND is again on my radar screen since with two approved products, LGND has a good change of a brighter future. In my recent posts, I criticized the high burn rate, which forces the LGND management to search for new fundings enevitable leading to stock dilution. This gets more and more difficult since investors discount this through lower stock prices. The ELAN deal is a good example for this kind of funding deals. According the last quarterly report,LGND has burned through 354M$, which includes acquisition costs. The burnrate stated by management runs at 30M$ per year only but I prefer to include acquisition costs, since without acquisitions, LGND would not have the products and the pipeline. I still regard the Seragen deal as negative. The total cost of the Seragen deal was 83.8M$,again paid with LGND stock. The current cash position is uncomfortably low at about 39M$ So much about the present. LGND has two products on the market, for niche indications (Karposis sarkoma and CTLC cancer. I am not sure about the market potential, but a somewhat sceptical guess would be about 80M$ peak sales. This almost certainly will not lead to profits this year and may be barely enough to break even next year (if nothing goes wrong. The company maker/breaker will be the Targetin indication for breast cancer. If this goes well, the company may go to 500M$ revenue (not more, since my guess is, they will have to sign up a marketing partner to get the sales force access). However, since the Diabetes studies for Targeting went bust because of side effects, the success of Targetin not only depends on efficiacy, but also on the severity of sides effects. This could well limit the market potential of Targetin. The rest of the pipeline is not worth that much in the near future, since most are licensed out to partners for singe digit royalities (most likely for the lower singe digits) and later stage products are years away from the market. My investment conclusion is that LGND is a higher risk bet amongst the biotechs. The liquidity cushion is quite thin, and when revenues won't pour in during 1999/2000 the future will look very bleak. However,if ONTAK and Panretin sell reasonable well and finally target is a success,LGND may be a 5 bagger. This makes LGND a very interesting spekulative investment. However, I am somewhat concerned, that the most recent weakness is due to bad news leaking out from the Targetin trials. If this is the case we may well look at 5$ per share. (Sorry for my poor English..its my second language..)